Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment
INDIANAPOLIS, June 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a potential
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
TOKYO, June 8, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced results from the Phase 3 DOLOMITES study, evaluatin
Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 7, 2020 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A s
Calquence Showed Promising Clinical Improvement in Majority of 19 Hospitalised COVID-19 Patients
June 5, 2020 -- Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcome
The University of Queensland, CEPI and CSL Partner to Advance Development and Manufacture of COVID-19 Vaccine Candidate
June 5, 2020, Oslo, Melbourne and Brisbane -- CEPI, the Coalition for Epidemic Preparedness Innovations, CSL (ASX:CSL) and The University of Queensland (UQ) today announced that they have entered into
GSK Announces New Data Presentations from the DREAMM Programme Exploring Investigational Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma
04 June 2020 -- GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/r
AstraZeneca Takes Next Steps Towards Broad and Equitable Access to Oxford University’s COVID-19 Vaccine
4 June 2020 -- AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalit
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) -- ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive he
INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea
SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnersh
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announc
Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology
NEW YORK--(BUSINESS WIRE) June 03, 2020 -- Pfizer Inc. (NYSE: PFE) announced today that JAMA Dermatology has published complete results from the second Phase 3 monotherapy pivotal study (JADE MONO-2)
BerGenBio Confirms First Covid-19 Patient Dosed With Bemcentinib in ACCORD Trial
Bergen, Norway - 02 June 2020 -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces
News
- CLINIEXPERT -
Int'l Clinical Service Expert
We are the leader
Because of our professionism
